SCHEMBL2194786

SCHEMBL2194786

c1ccc(COc2ccc3ncn(-c4ccccc4)c3n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.70
ATM Q13315 1/20 0.43
CYP1A2 P05177 1/20 0.43
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
HTR1A P08908 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
HTT P42858 2/20 0.41
PKM P14618 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
MAPK10 P53779 1/20 0.40
NCOA1 Q15788 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
HCAR1 Q9BXC0 2/20 0.39
FGFR1 P11362 1/20 0.39
IKBKE Q14164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195321 0.91 PDE10A (0.60) PDE10AATMCYP1A2HTR3EHTR3B
SCHEMBL2191698 0.91 PDE10A (0.60) PDE10AATMCYP1A2HTR3EHTR3B
SCHEMBL2194911 0.83 PDE10A (0.51) PDE10AATMCYP1A2HTR3EHTR3B
SCHEMBL2194185 0.82 PDE10A (0.51) PDE10AATMHTR3EHTR3BHTR1A
SCHEMBL31068655 0.81 PDE10A (0.48) PDE10ACYP1A2HTR3EHTR3BHTR1A
SCHEMBL2193026 0.76 HCAR1 (0.49) PDE10ACYP1A2HTR3EHTR3BHTR1A
SCHEMBL2193301 0.75 HTR3E (0.43) PDE10AHTR3EHTR3BHTR1AHTR3A
SCHEMBL2195431 0.74 CDK1 (0.47) PDE10AHTR3EHTR3BHTR1AHTR3A
SCHEMBL2194604 0.72 FGFR1 (0.50) PDE10AHTTHCAR1FGFR1
SCHEMBL1165233 0.72 PDE10A (0.50) PDE10AHTTALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 PDE10A 2688/4885ATM 4515/4885CYP1A2 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.